These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 2590077)

  • 1. Post marketing surveillance of new drugs. Patient safety in the hands of GPs.
    Marley JE
    Aust Fam Physician; 1989 Sep; 18(9):1133-5. PubMed ID: 2590077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-marketing surveillance of drugs.
    Bell KD
    Med J Aust; 1991 Apr; 154(8):567. PubMed ID: 2064665
    [No Abstract]   [Full Text] [Related]  

  • 3. Cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval.
    Borer JS; Pouleur H; Abadie E; Follath F; Wittes J; Pfeffer MA; Pitt B; Zannad F
    Eur Heart J; 2007 Aug; 28(15):1904-9. PubMed ID: 17615083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacologic surveillance and safety evaluation of new drugs].
    Reys LL
    Acta Med Port; 1991; 4(3):141-6. PubMed ID: 1950664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post marketing surveillance. Traps for the unwary.
    Marley J; Mant A
    Aust Fam Physician; 1993 Jun; 22(6):1009-11, 1013. PubMed ID: 8338446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prescription for trouble: common drugs, hidden dangers. Tens of people are at risk.
    Consum Rep; 2006 Jan; 71(1):34-9. PubMed ID: 16491527
    [No Abstract]   [Full Text] [Related]  

  • 7. Adverse drug reactions: a review of relevant factors.
    Ajayi FO; Sun H; Perry J
    J Clin Pharmacol; 2000 Oct; 40(10):1093-101. PubMed ID: 11028248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The safety of drugs].
    de Cea Lavech de Chancy H
    Rev Clin Esp; 1990 Sep; 187(4):184-90. PubMed ID: 2091076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety surveillance in drug development: understanding the process and its implications for nephrology nursing.
    Browar S
    Nephrol Nurs J; 2002 Apr; 29(2):143-50. PubMed ID: 11997949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Post-marketing surveillance of drugs: epidemiologic approach].
    Stanulović M; Jakovljević V; Sabo A
    Med Pregl; 1987; 40(11-12):573-7. PubMed ID: 3331415
    [No Abstract]   [Full Text] [Related]  

  • 11. [Pharmaco-morbidity linking: a potential instrument for post-marketing surveillance].
    Stricker BH; Herings RM; Bakker A; Valkenburg HA; Sturmans F
    Ned Tijdschr Geneeskd; 1990 Sep; 134(39):1886-9. PubMed ID: 2215766
    [No Abstract]   [Full Text] [Related]  

  • 12. Short patent lives jeopardize drug and patient safety.
    Hondeghem LM; De Clerck F; Camm J
    J Cardiovasc Pharmacol; 2007 Oct; 50(4):353-7. PubMed ID: 18049301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-marketing surveillance of licensed medicinal and other products.
    Griffin JP
    Health Trends; 1981 Aug; 13(3):85-8. PubMed ID: 10258571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status of the drug safety monitoring system in Korea.
    Park BJ
    Pharmacoepidemiol Drug Saf; 2001; 10(6):557-60. PubMed ID: 11828840
    [No Abstract]   [Full Text] [Related]  

  • 15. [Drug safety. Notes about surveillance].
    Moreno Alvarez PJ; Madurga Sanz M
    Farm Hosp; 2004; 28(3):225-8. PubMed ID: 15222877
    [No Abstract]   [Full Text] [Related]  

  • 16. Improving medication safety: influence of a patient-specific prescriber feedback program on rate of medication reviews performed by Australian general medical practitioners.
    Roughead E; Pratt N; Peck R; Gilbert A
    Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):797-803. PubMed ID: 17476702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "Black box" 101: How the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk.
    Murphy S; Roberts R
    J Allergy Clin Immunol; 2006 Jan; 117(1):34-9. PubMed ID: 16387581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Propensity score methods in drug safety studies: practice, strengths and limitations.
    Wang J; Donnan PT
    Pharmacoepidemiol Drug Saf; 2001; 10(4):341-4. PubMed ID: 11760497
    [No Abstract]   [Full Text] [Related]  

  • 19. [Withdrawal of cerivastatin revealed a flaw of post-marketing surveillance system in the United States].
    Saito M; Hirata-Koizumi M; Miyake S; Hasegawa R
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2005; (123):41-5. PubMed ID: 16541751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Postmarketing surveillance of adverse reactions of drugs].
    Polli EE; Cortellaro M
    Ann Ital Med Int; 1989; 4(1):1-9. PubMed ID: 2702012
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.